ErvinSteveWoodleMD

General Surgery • Cincinnati, OH

Transplantation

Professor, Surgery, University of Cincinnati College of Medicine

Join to view full profile

Dr. Woodle is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Woodle's full profile

Already have an account?

Office
222 Piedmont Ave
Cincinnati, OH 45219
Phone+1 513-475-8787

Fax+1 513-475-7348

Summary

I am a board certified general surgeon and a multi organ transplant surgeon. I have expertise in transplant immunology, immunosuppressive drug development, and basic, translational, and clinical research with over 30 years in academia.

Most recently, our research has focused on characterizing rejection at the single cell level, and using single cell genomics to define rejection phenotypes and to identify cellular adaptation and resistance to rejection therapy, with the ultimate goal to develop enhanced rejection therapies for both cellular and humoral rejection.

Education & Training

University of California Davis HealthResidency, Surgery, 1982 - 1987
University of Texas Health Science Center at HoustonResidency, Surgery, 1980 - 1982
University of Texas Medical Branch School of MedicineClass of 1980

Certifications & Licensure

CA State Medical License 1982 - Present
OH State Medical License 1999 - 2025
IL State Medical License 1987 - 2002
TX State Medical License 1980 - 1988
American Board of Surgery Surgery

Awards, Honors, & Recognition

Leslie Brent Prize for Outstanding Publication in Transplantation Transplantation, 2022

Clinical Trials

Randomized Trial for Mixed Acute Rejection Start of enrollment: 2008 Sep 01
Completed
Phase 2
Desensitization in Kidney Transplantation Start of enrollment: 2009 May 01
Completed
Phase 4
Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients Start of enrollment: 2019 Oct 14
Terminated
Phase 3
B-Cell Targeted Carfilzomib Desensitization Start of enrollment: 2014 Dec 01
Recruiting
Phase 1
Roles: Contact, Principal Investigator, Sponsor-Investigator
Quantitating the Impact of Plerixafor Start of enrollment: 2015 Aug 01
Recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator, Sponsor-Investigator
Join now to see all

Publications & Presentations

PubMed

456 citations
The immune cell landscape in kidneys of patients with lupus nephritis
Arnon Arazi, Deepak A. Rao, Celine C. Berthier, Anne Davidson, Yanyan Liu
Nature Immunology. 2019-06-17
18 citations
Early Corticosteroid Cessation vs Long-term Corticosteroid Therapy in Kidney Transplant Recipients: Long-term Outcomes of a Randomized Clinical Trial.
E. Steve Woodle, John S. Gill, Stephanie Clark, Darren Stewart, Rita R. Alloway
JAMA Surgery. 2021-02-03
24 citations
Cadherin-11, Sparc-related modular calcium binding protein-2, and Pigment epithelium-derived factor are promising non-invasive biomarkers of kidney fibrosis.
Insa M. Schmidt, Mia R. Colona, Bryan Kestenbaum, Leonidas G. Alexopoulos, Ragnar Palsson
Kidney International. 2021-09-01